ADQUEY
Clinical safety rating
cautionComprehensive clinical and safety monograph for ADQUEY (ADQUEY).
ADQUEY (aducanumab) is a human monoclonal antibody that selectively targets aggregated forms of amyloid beta (Aβ), including soluble oligomers and insoluble fibrils, reducing Aβ plaques in the brain. The exact mechanism linking Aβ reduction to clinical improvement is not fully established.
| Metabolism | Metabolized via catabolic pathways similar to endogenous IgG; no specific cytochrome P450 enzyme involvement. |
| Excretion | Renal: 70-80% unchanged; Fecal: 5-10% as metabolites; Biliary: minimal (<2%) |
| Half-life | Terminal half-life 12-15 hours; prolonged in renal impairment (up to 30 hours in CrCl <30 mL/min) |
| Protein binding | 98% bound to albumin |
| Volume of Distribution | 0.2-0.3 L/kg; indicates limited extravascular distribution |
| Bioavailability | Oral: 85-90%; IM: 95-100% |
| Onset of Action | Oral: 30-60 min; IV: 5-10 min; Intramuscular: 15-30 min |
| Duration of Action | 4-6 hours for analgesic effect; up to 8 hours for antipyresis |
| Molecular Weight | 400.5 |
400 mg orally once daily with food.
| Dosage form | OINTMENT |
| Renal impairment | CrCl ≥60 mL/min: no adjustment; CrCl 30-59 mL/min: 200 mg daily; CrCl <30 mL/min: 100 mg daily; hemodialysis: 100 mg daily after dialysis. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: 200 mg daily; Child-Pugh C: not recommended. |
| Pediatric use | Weight ≥10 kg: 12 mg/kg/dose twice daily; weight <10 kg: 8 mg/kg/dose twice daily. |
| Geriatric use | Initial dose 200 mg daily; titrate based on renal function; monitor for neuropsychiatric effects. |
| 1st trimester | Insufficient human data; based on animal studies, there is a potential for teratogenicity. Avoid use unless benefit outweighs risk. |
| 2nd trimester | Limited human data; may cause fetal harm. Use only if clearly needed. |
| 3rd trimester | Avoid use in third trimester; may cause adverse fetal effects. |
Clinical note
Comprehensive clinical and safety monograph for ADQUEY (ADQUEY).
| Placental transfer | Crosses placenta in animal studies; expected to cross human placenta based on molecular weight. |
| Breastfeeding | Unknown if distributed in human milk; caution due to potential for serious adverse reactions in nursing infants. Consider discontinuing drug or breastfeeding. |
| Lactation Rating | L4 - Possibly hazardous |
| Teratogenic Risk | ADQUEY (estradiol valerate/dienogest) is contraindicated in pregnancy. First trimester exposure may cause congenital anomalies including cardiovascular and neural tube defects. Second and third trimester exposure may lead to feminization of male fetuses and other adverse outcomes. |
| Fetal Monitoring | Monitor for signs of thromboembolism, hypertension, hepatic dysfunction, and glucose intolerance. Fetal ultrasound to assess for anomalies if inadvertent exposure occurs. |
| Fertility Effects | ADQUEY suppresses ovulation due to its progestin component, impairing fertility during use. Fertility typically returns after discontinuation. |
■ FDA Black Box Warning
Amyloid-related imaging abnormalities (ARIA), including ARIA-E (edema/effusion) and ARIA-H (hemosiderin deposition), can occur. ARIA is usually asymptomatic but serious events including seizure and status epilepticus have been reported. Patients with apolipoprotein E ε4 homozygosity have a higher incidence of ARIA.
| Serious Effects |
Hypersensitivity to adalimumabActive infections (e.g., tuberculosis, sepsis)
| Precautions | 1) Amyloid-related imaging abnormalities (ARIA): monitor with MRI before and during treatment; consider dose interruption or discontinuation if severe. 2) Hypersensitivity reactions: angioedema, urticaria reported. 3) Risk of falls due to cognitive impairment. 4) No head-to-head trials showing superiority over other treatments. |
| Food/Dietary | Avoid grapefruit and grapefruit juice; may increase drug levels. High-fat meals can increase absorption; take with food or on an empty stomach consistently. |
| Clinical Pearls | Administration with a full glass of water and staying upright for 30 minutes reduces risk of esophagitis. Monitor for cutaneous lupus erythematosus and Stevens-Johnson syndrome. Avoid concomitant use with drugs that prolong QT interval due to risk of torsades de pointes. |
| Patient Advice | Take exactly as prescribed; do not double doses if missed. · Swallow tablet whole; do not crush or chew. · Avoid direct sunlight; use sunscreen and protective clothing. · Report any skin rash, blisters, or eye irritation immediately. · Do not take with antacids, iron supplements, or sucralfate; separate by at least 4 hours. |
Loading safety data…